Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

OBJECTIVE: To determine if the dipeptidyl peptidase-4 inhibitor vildagliptin more effectively inhibits glucagon levels than the sulfonylurea glimepiride during a meal. RESEARCH DESIGN AND METHODS: Glucagon responses to a standard meal were measured at baseline and study end point (mean 1.8 years) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahrén, Bo, Foley, James E., Ferrannini, Ele, Matthews, David R., Zinman, Bernard, Dejager, Sylvie, Fonseca, Vivian A.
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2010
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2845014/
https://www.ncbi.nlm.nih.gov/pubmed/20067974
http://dx.doi.org/10.2337/dc09-1867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2845014/
https://www.ncbi.nlm.nih.gov/pubmed/20067974
http://dx.doi.org/10.2337/dc09-1867

Ejemplares similares